Parkinson’s Disease – Alpha-synuclein Transgenic Mouse Models
Test potential therapeutics for Parkinson’s disease and other synucleinopathies using InnoSer’s Alpha-synuclein Transgenic Mouse Models with alpha-synuclein deposition and downstream pathological events
Alpha-synuclein Transgenic Mouse Models Characteristics
Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor systems in early stages, leading to symptoms such as trembling, slowing of movement, and muscle stiffness. The distinct disease mechanism can be modelled in different Parkinson’s disease mouse models. Alpha-synuclein (α-syn) inclusions are the main histopathological hallmark correlating with clinical symptoms of not only PD, but also other synucleinopathies such as dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA).
InnoSer offers fee-for-service alpha-synuclein (α-syn) transgenic mouse models. Accordingly, alpha-synuclein transgenic mouse models faithfully recapitulate the α-syn pathophysiology found in PD, DLB and MSA. As various models of α-syn pathology are available; the choice of the model ultiamtely depends on your compound’s mechanism of action and your research goals. Moreover, InnoSer offers research services with multiple other Parkinson’s disease mouse models, including alpha-synuclein seeding models and the MPTP mouse model. As each model is unique, modelling distinct pathophysiological aspects of PD, we recommend you discuss the most appropriate model with our neurology study directors.Â
✓ Human α-syn models.
✓ A53T α-syn models (e.g. M83).
✓ Seeding in α-syn transgenic models.
Take advantage of InnoSer’s behavioural research expertise, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience modelling PD in vivo using transgenic mouse lines and other neurodegenerative diseases. Our neurology experts help guide your decision on choosing the best model fit for your current research goals.Â
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies).Â
Your Neurology Research Starts Here.
Choose the Right Model for Your Research with Confidence
Alpha-synuclein Transgenic Mouse Models Sample Data
Homozygous M83+/+ A53T (aSyn) transgenic mice show increased slips on the Balance beam at 8 months of age, compared to WT controls.
The Balance Beam sensorimotor coordination test scores the ability of mice to traverse a stationary horizontal rod. Coordination of the mouse is measured by the latency to cross the beam and the number of foot slips made.Â
Alpha-synuclein Transgenic Mouse Models Readouts
Biological Readouts
Test the efficacy of your treatments with the following biological readouts:Â
 Â
- MSD: Plasma, CSF, and brain (α-syn, cytokines, NfL)Â
- (Digital) histopathologyÂ
- Immunohistochemistry (e.g. α-syn, neuroinflammation, neurodegeneration)Â
- Immunofluorescence and FISH
The People Behind Your Research
Thomas Vogels, PhD, In Vivo Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Discover Other Relevant Rare Genetic Disease Models
Discover InnoSer’s Latest Research
InnoSer and CureSHANK partner to launch industry-quality preclinical testing service for Phelan-McDermid syndrome (PMS) treatments
Together, CureSHANK, a nonprofit research foundation, and InnoSer, preclinical research CRO, aim to remove barriers to drug development for Phelan-McDermid syndrome treatment by providing the global research community with accessible and industry-standard preclinical...
Accelerating Angelman Syndrome Research: InnoSer now offers Angelman Syndrome Mouse Model
As part of our ongoing efforts to support the development of new therapeutics for rare genetic neurological diseases, we are proud to introduce a new preclinical research model for Angelman Syndrome within InnoSer’s portfolio. In collaboration with Professor Ype...
InnoSer Partners with Kabuki Syndrome Foundation to Advance Therapeutic Development for Kabuki Syndrome
InnoSer to serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in the Kmt2d+/βGeo mouse model. This collaboration aims to empower leading biotech and pharma innovators to perform rigorous studies informing clinical trial readiness of...
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. Â The ADPD 2025 Conference is...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. InnoSer’s facilities in the Netherlands and Belgium have been AAALAC-accredited since 2016 and 2020, respectively. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com